Loading clinical trials...
Loading clinical trials...
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination With the MEK Inhibitor GSK1120212 in Subjects With BRAF Mutant Metastatic Melanoma
Conditions
Interventions
GSK2118436
GSK1120212
Locations
15
United States
Novartis Investigative Site
Los Angeles, California, United States
Novartis Investigative Site
San Francisco, California, United States
Novartis Investigative Site
Aurora, Colorado, United States
Novartis Investigative Site
New Haven, Connecticut, United States
Novartis Investigative Site
Tampa, Florida, United States
Novartis Investigative Site
Lutherville-Timonium, Maryland, United States
Start Date
March 26, 2010
Primary Completion Date
May 31, 2012
Completion Date
February 27, 2018
Last Updated
July 5, 2019
NCT07336732
NCT07486219
NCT06696768
NCT06898450
NCT06842498
NCT07190248
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions